QC
KYTX icon

Quadrature Capital’s Kyverna Therapeutics KYTX Stock Holding History

Quadrature Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$331K Sell
38,411
-18,958
-33% -$158K ﹤0.01% 932
2025
Q4 		$539K Buy
+57,369
New +$426K 0.01% 675
2025
Q3 		– Sell
-12,392
Closed -$38K – 1566
2025
Q2 		$38K Sell
12,392
-1,160
-9% -$2.87K ﹤0.01% 974
2025
Q1 		$26.2K Buy
+13,552
New +$40K ﹤0.01% 1020

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Quadrature Capital's KYTX Position: Q1 2026 in Review

Quadrature Capital reduced its Kyverna Therapeutics (KYTX) stake by 33% in Q1 2026, selling an estimated $158K and leaving 38,411 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

Quadrature Capital first reported a position in KYTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $539K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Quadrature Capital held 38,411 shares of Kyverna Therapeutics worth $331K as of Q1 2026.
  • Quadrature Capital sold 18,958 Kyverna Therapeutics shares in Q1 2026, an estimated $158K.
  • Kyverna Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #932 holding.
  • Quadrature Capital first reported a position in Kyverna Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Quadrature Capital's Kyverna Therapeutics position peaked at $539K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.